P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples